{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:macitentan",
  "owner": "cardio",
  "kind": "drug",
  "slug": "macitentan",
  "name": "Macitentan",
  "aliases": [
    "OPSUMIT"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Macitentan, sold as Opsumit, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group I) in adults, to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause fetal harm. That risk concerns the unborn child and is recorded separately.",
  "summary_technical": "RxNorm ingredient 1442132; UNII Z9K9Y9WMVL. MeSH has no descriptor for macitentan (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Actelion Pharmaceuticals US, Inc. label for Opsumit, application NDA204410 (approved 2013-10-18 as a new molecular entity in Drugs@FDA), effective 2025-04-11 in openFDA. A combination product of macitentan and tadalafil (Opsynvi, NDA218490) is a separate product and was not read. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "1442132",
      "normalized_value": "1442132",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "Z9K9Y9WMVL",
      "normalized_value": "Z9K9Y9WMVL",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says macitentan is an endothelin receptor antagonist that inhibits the binding of endothelin-1 to both the ET A and the ET B receptor."
  },
  "content_digest": "072e1436ef31f6f703b577ec3e911bbac0dcfb967494906f9cb7d3b0e073c73a",
  "review": {
    "content_digest": "072e1436ef31f6f703b577ec3e911bbac0dcfb967494906f9cb7d3b0e073c73a",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-opsumit-label-fetal-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:macitentan",
      "category": "safety",
      "statement": "The same US label of Opsumit carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.",
      "context": {
        "id": "cardio:ctx-fda-opsumit-label-fetal-risk",
        "label": "The developing fetus, for a person taking macitentan during pregnancy, as described in a US label boxed warning",
        "recipient": "fetal",
        "population": "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Fetus during pregnancy; the passage read gives no gestational ages",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA204410.",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20250411.",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], title",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-OPS-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], first paragraph",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-OPS-LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "5b58d697efbc1333376ce90364a3de3bbf92be0ab6f1ca8a3a759d942c1ed00f",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-opsumit-label-fetal-warning.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-opsumit-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:macitentan",
      "category": "descriptive",
      "statement": "The US label of Opsumit (macitentan tablets, Actelion Pharmaceuticals US, Inc., application NDA204410; the version dated 2025-04-11 in openFDA) describes macitentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group I) in adults to reduce the risks of disease progression and hospitalization for pulmonary arterial hypertension.",
      "context": {
        "id": "cardio:ctx-fda-opsumit-label-us",
        "label": "Adults with pulmonary arterial hypertension, as described in the US label of Opsumit",
        "recipient": "adult",
        "population": "Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA204410.",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20250411.",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-OPS-LB-04, Q-K29-OPS-LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-opsumit-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:33Z",
            "content_hash": "d58418de14a806412a924192c2a9f5347b6faa1b49ba412aeffe7e31c1d9eb71",
            "source_effective_date": "2025-04-11",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-opsumit",
            "source_type": "regulator",
            "title": "openFDA drug label record for Opsumit (macitentan tablets), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221e484a50-55db-4b85-8c57-6cd1b0353abd%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1e484a50-55db-4b85-8c57-6cd1b0353abd (manufacturer Actelion Pharmaceuticals US, Inc., application NDA204410), returned on 2026-11-18. The label text is dated 2025-04-11 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used. The combination product Opsynvi (macitentan and tadalafil, NDA218490) was not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-opsumit.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "45573b1e06f71ee64b061d2bb23e15dc5943bdc51ad67d489e362d9e19d41791",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-opsumit-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Macitentan is an endothelin receptor antagonist (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:endothelin-receptor-antagonists",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-1442132-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to reduce the risks of disease progression and hospitalization, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-opsumit-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "A separate US product combines macitentan and tadalafil, according to its label",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:tadalafil",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/macitentan/",
  "context_path": "api/v1/context/cardio--macitentan.md"
}
